'The R&D process is highly regulated, wherever we operate. As scientific advances raise new issues, we work closely with the regulators, policy makers and stakeholders to develop any new or refined standards. We have our own internal standards and systems to ensure that we comply with or exceed all guidelines, regulations and legal requirements.'
That being the case, it must be another GlaxoSmithKlein that just killed at least 12 babies in Argentina, during trials, which are on-going, despite the deaths. The report states:
'According to pediatrician Ana Maria Marchese, who works at the children's hospital in the provincial capital where the studies are being conducted, "because they can't experiment in Europe or the United States, they come to do it in third-world countries." '
But to Enrique Smith, one of the leading doctors involved in the trial:
"Only 12 have died throughout the country, which is a very low figure if we compare it with the deaths produced by respiratory illnesses caused by the pneumococcal bacteria".
In other words, a price worth paying, so a global corporation can profit.
(Hat tip: Informationliberation)